ABCL Stock Price, Analysis & Fundamentals

Analysis

AbCellera Biologics Inc. operates within the healthcare sector and biotechnology industry, with a market capitalization of $1.03B. The company has 596 employees. From a financial perspective, AbCellera's profitability is marked by negative margins: Gross Margin stands at 0.0%, Operating Margin at -851.8%, and Profit Margin also at 0.0%. Returns on equity and assets are similarly negative, with ROE at -16.8% and ROA at -10.4%. The company's balance sheet shows $142.22M in debt against a cash reserve of $495.67M, resulting in a Debt to Equity ratio of 14.75. The company's valuation metrics reveal a P/E Ratio (TTM) of N/A and a Forward P/E of -4.97. Revenue growth has been notable, with a year-over-year increase of 37.6%. However, there is no information on dividend payments or yield as the Dividend Yield is listed as N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Visit website →

ABCL

Price History (1Y)

Analysis

About AbCellera Biologics Inc.

Key Statistics

Company Info